Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trialSalah‐Eddin Al‐Batran, Alexander Reichart, Nils Homann et al.|The Lancet|2019Cited by 2.6k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trialIan Judson, Winette T.A. van der Graaf, C. Hermans et al.|The Lancet Oncology|2014Cited by 1.2k
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trialGunnar Folprecht, Claus‐Henning Köhne, Thomas Gruenberger et al.|The Lancet Oncology|2009Cited by 960
Toxicity of platinum compoundsJörg T. Hartmann, Hans‐Peter Lipp|Expert Opinion on Pharmacotherapy|2003Cited by 576
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trialRalf‐Dieter Hofheinz, Andreas Hochhaus, Frederik Wenz et al.|The Lancet Oncology|2012Cited by 505